Chemotherapy of recurrent medulloblastoma with combined procarbazine, CCNU, and vincristine

摘要: Seventeen patients with recurrent medulloblastoma were treated a combination of three drugs: procarbazine, CCNU, and vincristine (PCV). Tumor recurrence was documented at varying periods following surgery radiotherapy. Among 16 evaluable patients, ten showed response to PCV on the basis subjective neurological improvement decrease in tumor size by radiological criteria. Five designated as having stable disease no change status size. One patient uninterrupted progression disease. The median time for all 45 weeks. Significnat myelotoxicity, exacerbated prior spinal irradiation, compromised therapy. After an initial response, it often necessary reduce higher doses CCNU procarbazine that caused concomitant bone-marrow toxicity; consequence lowered doses, then frequently observed. authors conclude is effective form palliative therapy medulloblastoma.